|
Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment: The CARACAS study. |
|
|
Consulting or Advisory Role - Amgen; Lilly; Merck Serono; SERVIER |
Speakers' Bureau - Bristol-Myers Squibb; Lilly; Merck Serono; Roche; Servier |
Research Funding - Amgen; Merck Serono |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Sanofi |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Amgen; Kiowa Kirin; Merck; Sanofi; SERVIER |
Travel, Accommodations, Expenses - Amgen; Janssen; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Merck Serono; Sanofi |
Speakers' Bureau - Amgen; Bayer; Eisai; Eisai; Merck Serono; Roche/Genentech; SERVIER |
Research Funding - Bayer; Celgene (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Celgene; Merck Serono; SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Merck |
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly; Roche; SERVIER |
Travel, Accommodations, Expenses - Bayer; Roche; SERVIER |